Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer

James A Radosevich, Michael Babich LabyRx Immunologic Therapeutics (USA) Limited, Sacramento, California, USACorrespondence: James A Radosevich 1009 Johnson Ct, Belvidere, IL 61008 Tel +1 530 330 5888Email jrados@labyrx.comAbstract: A paradigm shift is currently underway on the relationship between...

Full description

Bibliographic Details
Main Authors: Radosevich JA, Babich M
Format: Article
Language:English
Published: Dove Medical Press 2019-11-01
Series:OncoTargets and Therapy
Subjects:
Online Access:https://www.dovepress.com/labyrinthin-the-tumor-marker-recognized-by-mca-44-3a6-a-case-for-pan-t-peer-reviewed-article-OTT

Similar Items